Cantor Fitzgerald, L. P. Astria Therapeutics, Inc. Transaction History
Cantor Fitzgerald, L. P.
- $90.6 Billion
- Q2 2025
A detailed history of Cantor Fitzgerald, L. P. transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Cantor Fitzgerald, L. P. holds 54,635 shares of ATXS stock, worth $664,361. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,635Holding current value
$664,361% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATXS
# of Institutions
110Shares Held
49.3MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$78.9 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.52MShares$55 Million1.28% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$49.9 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$43.2 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$42.8 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $185M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...